![Brisbane image](https://groundnews.b-cdn.net/interests/c538f996a64d002948bedaaec2a9f300faeed495.jpg)
News from Brisbane
Stay current with all the latest and breaking news about Brisbane, compare headlines and perspectives between news sources on stories happening today. In total, 69 stories have been published about Brisbane which Ground News has aggregated in the past 3 months.
Weather
17°C
![Weather in Brisbane for Saturday](https://openweathermap.org/img/wn/03d@2x.png)
Saturday
14° | 17°C
![Weather in Brisbane for Saturday](https://openweathermap.org/img/wn/02d@2x.png)
Sunday
14° | 18°C
![Weather in Brisbane for Sunday](https://openweathermap.org/img/wn/02d@2x.png)
Monday
14° | 18°C
![Weather in Brisbane for Monday](https://openweathermap.org/img/wn/04d@2x.png)
Tuesday
14° | 19°C
![Weather in Brisbane for Tuesday](https://openweathermap.org/img/wn/02d@2x.png)
Wednesday
14° | 19°C
![Weather in Brisbane for Wednesday](https://openweathermap.org/img/wn/04d@2x.png)
Thursday
14° | 18°C
![Weather in Brisbane for Thursday](https://openweathermap.org/img/wn/04d@2x.png)
Local News Publishers
Suggest a source
Looking for a source we don't already have? Suggest one here.Top Brisbane News
Latest News Stories
Brisbane · BrisbaneSingle Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly Statistically Significant and Clinically Meaningful 2.4-fold Improvement in GBS-DS vs. Placebo at Week 8, p=0.0058 ANX005 Demonstrated Early and Sustained Improvements in Key Secondary Endpoints Including Muscle Strength, Nerve Damage and Ventilation ANX005 Displayed Rapid Target Engagement and was Generally Well-Tolerated Across Doses Real-World Evidence (RWE) Compara…See the Story
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome - Annexon (NASDAQ:ANNX)
100% Center coverage: 1 sources
Brisbane · Brisbane72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract; Rapid and sustained improvements in hematuria over 36 weeks, with resolution in significantly greater percentage of participants than placebo; BRISBANE, Calif., May 25, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for pa…See the Story
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress - Vera Therapeutics (NASDAQ:VERA)
100% Center coverage: 1 sources
Brisbane · BrisbaneBRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on May 1, 2024, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 15,000 shares of Class A common stock and restricted stock units (RSUs) for 7,500 shares of Class A common stock to three new employees under Vera's 2024 Inducement Plan (the Inducement…See the Story
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vera Therapeutics (NASDAQ:VERA)
100% Center coverage: 1 sources